Witt W, Stürzebecher S, Müller B
Research Laboratories of Schering AG, Berlin, FRG.
Thromb Res. 1988 Sep 15;51(6):607-16. doi: 10.1016/0049-3848(88)90144-2.
The stable PGI2-analogue iloprost and the TXA2-receptor antagonist sulotroban were investigated for possible cooperative effects on platelet function and experimental thrombus formation in guinea pigs and rats. Iloprost and sulotroban inhibit intravascular platelet aggregation in guinea pigs and rats induced by the stable endoperoxide U 46.619 and collagen, with iloprost being the more potent and (for collagen) more efficacious drug. Combinations of both compounds show synergistic or additive effects on in vivo platelet function. Thrombus formation in rats induced by vascular damage is strongly reduced by combining doses of iloprost and sulotroban (BM 13.177) which given alone are ineffective. These results suggest a cooperative enhancement of antiplatelet and antithrombotic effects for combinations of iloprost and sulotroban. In view of disadvantages of currently used platelet inhibitors this cooperativity may offer a new approach in antiplatelet therapy.
研究了稳定的前列环素类似物伊洛前列素和血栓素A2受体拮抗剂舒洛地班对豚鼠和大鼠血小板功能及实验性血栓形成的可能协同作用。伊洛前列素和舒洛地班可抑制豚鼠和大鼠体内由稳定内过氧化物U 46.619和胶原诱导的血管内血小板聚集，其中伊洛前列素作用更强，且（对于胶原）是更有效的药物。两种化合物的组合对体内血小板功能显示出协同或相加作用。单独使用无效的伊洛前列素和舒洛地班（BM 13.177）联合给药可显著减少大鼠血管损伤诱导的血栓形成。这些结果表明伊洛前列素和舒洛地班组合具有协同增强的抗血小板和抗血栓作用。鉴于目前使用的血小板抑制剂存在的缺点，这种协同作用可能为抗血小板治疗提供一种新方法。
